BMS 844421

Drug Profile

BMS 844421

Alternative Names: BMS-844421; BMS-PCSK9Rx

Latest Information Update: 27 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Bristol-Myers Squibb
  • Class Antihyperlipidaemics; Antisense oligonucleotides
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 31 Dec 2011 BMS 844421 is no longer licensed to Bristol-Myers Squibb worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top